Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.

Human CC chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1), is a member of the β chemokine family whose actions are mediated through the G-protein-coupled receptor CCR2. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. CNTO 888, a neutralizing human anti-CCL2 antibody, was derived by antibody phage display. The antibody binds human CCL2 with high affinity (K(D)=22 pM) and inhibits CCL2 binding to its receptor. The crystal structure of the CNTO 888 Fab alone and in complex with the monomeric form of CCL2 (P8A variant) was determined at 2.6 Å and 2.8 Å resolution, respectively. CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site. The epitope of CNTO 888 does not overlap with the dimerization site of CCL2, and thus its inhibitory activity is not expected to result from interference with the oligomeric state of CCL2. Comparison of the X-ray-determined epitopes of CNTO 888 and another CCL2-neutralizing antibody, 11K2, provides insight into the molecular basis of antibody selectivity and functional inhibition.

[1]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[2]  U. Matulonis,et al.  Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[3]  P. Kolattukudy,et al.  Monocyte Chemotactic Protein (MCP)-1 Promotes Angiogenesis via a Novel Transcription Factor, MCP-1-induced Protein (MCPIP)* , 2008, Journal of Biological Chemistry.

[4]  K. Jarnagin,et al.  Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B* , 1998, The Journal of Biological Chemistry.

[5]  M. Copin,et al.  MCP-1 secretion in lung from nonsmoking patients with coal worker's pneumoconiosis. , 1997, The European respiratory journal.

[6]  K. Sugimura,et al.  Ig L-chain shuffling for affinity maturation of phage library-derived human anti-human MCP-1 antibody blocking its chemotactic activity. , 2008, Journal of biochemistry.

[7]  F. Balkwill,et al.  Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  G. Stamp,et al.  The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.

[9]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[10]  E. Leonard,et al.  Human monocyte chemoattractant protein-1 (MCP-1). , 1990, Immunology today.

[11]  J. Alcamí,et al.  Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. , 2001, Arthritis and rheumatism.

[12]  B. Rollins,et al.  Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. , 1991, The American journal of pathology.

[13]  K. Pienta,et al.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. , 2009, Cancer research.

[14]  G. Gilliland,et al.  Synthesis by native chemical ligation and crystal structure of human CCL2 , 2010, Biopolymers.

[15]  D. Salant,et al.  RANTES and Monocyte Chemoattractant Protein–1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis , 1997, The Journal of experimental medicine.

[16]  Daved H. Fremont,et al.  Dual GPCR and GAG mimicry by the M3 chemokine decoy receptor , 2007, The Journal of experimental medicine.

[17]  F. Breedveld,et al.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[18]  Tracy M. Handel,et al.  Structural Basis of Chemokine Sequestration by a Herpesvirus Decoy Receptor , 2002, Cell.

[19]  D. Galson,et al.  Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.

[20]  A. Mantovani,et al.  A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. , 1994, Journal of immunological methods.

[21]  J. Ward,et al.  Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. , 2000, Blood.

[22]  U. Matulonis,et al.  Cytokines IL-1b, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFa in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel , 1999 .

[23]  H. V. van Vlijmen,et al.  Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. , 2006, Protein engineering, design & selection : PEDS.

[24]  G. Obmolova,et al.  Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: Papain digestion of mAb and transient expression in mammalian cells. , 2009, Protein expression and purification.

[25]  B. Stoddard,et al.  Microseed matrix screening to improve crystals of yeast cytosine deaminase. , 2004, Acta crystallographica. Section D, Biological crystallography.

[26]  B. Rollins,et al.  The human homolog of the JE gene encodes a monocyte secretory protein , 1989, Molecular and cellular biology.

[27]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[28]  R. Sweet,et al.  Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies. , 2008, Human antibodies.

[29]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  L. Lally The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[31]  R. Poljak,et al.  Structural features of the reactions between antibodies and protein antigens , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  A. Honegger,et al.  The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. , 2008, Journal of molecular biology.

[33]  R. Strieter,et al.  Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4+ T cell activation. , 1998, Journal of immunology.

[34]  J. Skehel,et al.  Structural evidence for recognition of a single epitope by two distinct antibodies , 2000, Proteins.

[35]  C. J. Beall,et al.  Conversion of monocyte chemoattractant protein-1 into a neutrophil attractant by substitution of two amino acids. , 1992, The Journal of biological chemistry.

[36]  K. Jarnagin,et al.  Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. , 1999, Biochemistry.

[37]  U. Frei,et al.  Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. , 2001, The American journal of pathology.

[38]  B. Rollins,et al.  Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. , 1994, The Journal of biological chemistry.

[39]  C. Mackay,et al.  Gene Profiling in Atherosclerosis Reveals a Key Role for Small Inducible Cytokines: Validation Using a Novel Monocyte Chemoattractant Protein Monoclonal Antibody , 2005, Circulation.

[40]  J. Kuratsu,et al.  Production and characterization of mouse monoclonal antibodies against human monocyte chemoattractant protein-1. , 1991, Journal of immunology.

[41]  Matthew J. Craig,et al.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.

[42]  J. Carton,et al.  Codon engineering for improved antibody expression in mammalian cells. , 2007, Protein expression and purification.

[43]  P. Domaille,et al.  Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. , 1996, Biochemistry.

[44]  W. Delano The PyMOL Molecular Graphics System , 2002 .